An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...

Wildwood Alpacas near Albrighton hosted extra-special, ticketed Mother's Day sessions from Friday (March 28) to Sunday. The ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Lilly's lepodisiran shows a 94% reduction in heart disease risk by lowering lipoprotein(a) levels, offering a breakthrough in cardiovascular innovation.

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

A Kalamazoo Township police officer and a suspect were hurt after shots were fired in Kalamazoo on Thursday, according to the ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

We will leave the Christmas movie scripting to the experts over at Hallmark, but what would a storybook ending look like for ...

Join the staff of White Violet Center for Eco-Justice and others as they host the upcoming Alpaca Yoga, scheduled to take ...